Omaima Degani, MD
Nephrology · Gurnee, ILNPI 1477618155
Payments from drug & device makers
Across 674 payments — averaging $330.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$55K
- AstraZeneca$50K
- Mallinckrodt Hospital Products Inc.$48K
- Novo Nordisk AS$39K
- Aurinia Pharma U.S., Inc.$13K
- Amgen$7K
- plus $11K from 29 others
Across 8 payments — averaging $209.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2K
What the payments were for
- Consulting fees$23,20113%
- Speaking & faculty fees$122,49167%
- Travel & lodging$19,46611%
- Food & beverage$17,94110%
- Education$4090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 123 | $54,604 |
| AstraZeneca(2 entities) | 134 | $49,927 |
| Mallinckrodt Hospital Products Inc. | 57 | $47,742 |
| Novo Nordisk AS | 104 | $39,243 |
| Aurinia Pharma U.S., Inc. | 17 | $13,335 |
| Amgen(2 entities) | 54 | $6,707 |
| Akebia Therapeutics Inc | 23 | $5,330 |
| Sanofi | 2 | $433 |
| Mallinckrodt Enterprises LLC | 7 | $422 |
| Bayer | 16 | $406 |
| Novo Nordisk | 8 | $363 |
| Fresenius USA Marketing, Inc. | 12 | $362 |
| Nxstage Medical, Inc. | 4 | $347 |
| Bard Peripheral Vascular, Inc. | 3 | $347 |
| Otsuka America Pharmaceutical, Inc. | 14 | $346 |
| ANI Pharmaceuticals, Inc. | 8 | $303 |
| Vifor Pharma, Inc. | 14 | $293 |
| Medtronic | 2 | $293 |
| Recor Medical Inc | 5 | $260 |
| Boston Scientific | 9 | $254 |
| OPKO Pharmaceuticals, LLC | 12 | $226 |
| Novartis | 8 | $210 |
| Lilly USA, LLC | 4 | $193 |
| Boehringer Ingelheim | 6 | $134 |
| Daiichi Sankyo Inc. | 5 | $109 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $106 |
| GSK | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Ardelyx, Inc. | 1 | $82 |
| Ultragenyx Pharmaceutical Inc. | 3 | $54 |
| Corcept Therapeutics | 1 | $36 |
| Scpharmaceuticals Inc. | 1 | $22 |
| AMAG Pharmaceuticals, Inc. | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$46,778
- FARXIGA$43,033
- Filspari$14,137
- LUPKYNIS$13,056
- KRYSTEXXA$5,509
- LOKELMA$4,975
- Vafseo$4,802
- CABLIVI$400
- ACTHAR$375
- Signia$269
- NXSTAGE SYSTEM ONE$220
- LUTONIX$143
- PURIFIED CORTROPHIN GEL$125
- JARDIANCE$122
- Tavneos$122
- Ozempic$122
- PARADISE RENAL DENERVATION SYSTEM$120
- LIBERTY SELECT CYCLER$106
How this compares
$222,750 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 129 | $113,459 |
| JardianceEmpagliflozin | 103 | $99,668 |
| VelphoroSucroferric Oxyhydroxide | 13 | $44,277 |
| VeltassaPatiromer Calcium Sorbitex | 36 | $42,251 |
| XphozahTenapanor Hcl | 11 | $30,264 |
| KerendiaFinerenone | 25 | $19,862 |
| InvokanaCanagliflozin | 28 | $14,107 |
| Cinacalcet Hcl | 27 | $10,880 |
| Sevelamer Carbonate | 68 | $9,112 |
| EliquisApixaban | 13 | $7,896 |
| DapagliflozinDapagliflozin Propanediol | 15 | $7,865 |
| ClinisolParenteral Amino Acid 15% No.5 | 19 | $3,395 |
| Clonidine | 24 | $3,103 |
| EdarbiAzilsartan Medoxomil | 12 | $2,993 |
| Bumetanide | 66 | $2,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $49,927 | $113,459129 claims |
| Boehringer IngelheimJardiance | $134 | $99,668103 claims |
| Fresenius USA Marketing, Inc.Velphoro | $362 | $44,27713 claims |
| BayerKerendia | $406 | $19,86225 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $303 | $44316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.
Other nephrology in Gurnee
- Rakhi KhannaGurnee$59K
- Myles WolfChicago$22.4M
- Suneel UdaniHinsdale$6.8M
- Paul CrawfordEvergreen Park$3.1M
- Beatrice ConcepcionChicago$2.6M
- April KennedyChicago$1.8M
- Khaleel SayeedChicago$1.7M
- Woojin James ChonHines$1.1M
- Mohammed AhmedBolingbrook$1.1M
- Tamara IsakovaChicago$763K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.